Protagonist Therapeutics, Inc.

Total Valuation

Protagonist Therapeutics, Inc. carries a market capitalization of 6.14B, placing it among publicly traded companies globally. Its enterprise value stands at 6.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Protagonist Therapeutics, Inc. currently has 64.23M shares outstanding.

Valuation Ratios

Protagonist Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 157.90. The price-to-sales ratio is 91.22, and the price-to-book ratio stands at -14.47.

Enterprise Valuation

On an enterprise value basis, Protagonist Therapeutics, Inc. trades at an EV/EBITDA multiple of 301.94 and an EV/FCF ratio of 212.23. The EV/Sales ratio of 83.96 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 316.21 provides insight into valuation relative to core operating earnings.

Financial Position

Protagonist Therapeutics, Inc. maintains a current ratio of 17.76, meaning it holds 17.8x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Stock Price Statistics

Protagonist Therapeutics, Inc.'s stock has gained approximately 86.8586% over the past 52 weeks. The 50-day moving average sits at 101.38, while the 200-day moving average is 84.58.

Income Statement

Over the trailing twelve months, Protagonist Therapeutics, Inc. generated 74.06M in revenue and converted that into -114.71M in net income, yielding earnings per share of -1.75. EBITDA reached -141.02M, while operating income came in at -142.46M.

Balance Sheet

Protagonist Therapeutics, Inc. holds 547.79M in cash and equivalents against 9.78M in total debt, resulting in a net debt position of -193.71M. Total book value stands at -466.89M, with working capital of 578.91M providing operational flexibility.

Cash Flow

Protagonist Therapeutics, Inc. produced -116.63M in operating cash flow over the past twelve months. After subtracting -1.26M in capital expenditures, free cash flow totaled -117.89M - equivalent to -1.84 per share.

Margins

Protagonist Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -192.36 and net profit margin of -154.88 provide insight into operational efficiency.

Dividends & Yields

Scores

Protagonist Therapeutics, Inc. posts an Altman Z-Score of 96.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.